Amundi Raises Holdings in Indivior PLC (NASDAQ:INDV)

Amundi lifted its position in Indivior PLC (NASDAQ:INDV) by 12.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 174,434 shares of the company’s stock after buying an additional 19,010 shares during the period. Amundi’s holdings in Indivior were worth $2,109,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Iron Triangle Partners LP bought a new stake in Indivior during the 3rd quarter valued at $8,243,000. Krensavage Asset Management LLC bought a new stake in Indivior during the third quarter valued at about $6,843,000. Stonepine Capital Management LLC purchased a new position in Indivior in the third quarter valued at about $2,632,000. Clark Estates Inc. NY bought a new position in Indivior in the third quarter worth about $2,477,000. Finally, Petrus Trust Company LTA purchased a new stake in shares of Indivior during the third quarter valued at about $1,251,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Up 3.2 %

INDV stock opened at $9.99 on Tuesday. The stock has a market capitalization of $1.38 billion, a PE ratio of -28.54 and a beta of 0.82. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $22.53. The firm has a 50 day moving average of $10.60 and a 200 day moving average of $10.47.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. On average, equities research analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on INDV shares. Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock. Finally, RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.